When do biologic drug patents expire and when will biosimilars launch?

United States Patent 10,695,415 Claim Scope and US Patent Estate for Transgenic Salmonella Typhi Ty21a Expressing Heterologous Shigella O-Antigen and Acid-Resistance Genes

Executive summary: US 10,695,415 is directed to a genetically engineered, chromosomally integrated Salmonella Typhi Ty21a vaccine strain that expresses heterologous Shigella sonnei O-antigen biosynthetic genes (with a specific wzz constraint) together with heterologous acid-resistance gene systems based on Shigella acid resistance enzymes including a YbaS/gad set. Dependent claims narrow to defined sequence identity windows for the wzz and YbaS loci, to additional O-antigen regions from specified Gram-negative taxa, and to specific oral vaccine and efficacy end-points (reducing shigellosis and/or typhoid fever). The claims are composition-of-matter and use (vaccine/administration outcomes) rather than manufacturing-process claims. The key infringement risk for competitors and generics lies in genetic design choices that still meet the specific identity thresholds, chromosomal integration requirement, and the coupled O-antigen plus acid-stability phenotype. Licensing and litigation leverage typically focuses on whether alternative constructs still “read on” the claim via (i) functional equivalence arguments versus (ii) strict sequence-identity and gene-specification limits.

What exactly does US 10,695,415 claim for transgenic Ty21a “with Shigella O-antigen + acid resistance” in the US?

Short answer: It claims (1) a transgenic Salmonella Typhi Ty21a with two chromosomally integrated heterologous gene sets: an O-antigen biosynthetic region from Shigella sonnei that includes a wzz gene meeting a specific sequence-identity/sequence-regional requirement, and an acid-resistance biosynthetic system comprising Shigella acid resistance enzymes that include a YbaS gene (and, in dependents, gadA/gadB/gadC variants). It also claims (2) vaccine compositions and oral vaccines containing that strain, with (3) human population efficacy statements framed as reduced incidence after exposure.

Independent claim 1: core technical and legal boundaries

Claim 1 is built from several stacked limitations that collectively narrow infringement:

A. Host and insertion site

Host: “transgenic Salmonella typhi Ty21a”
Integration: both heterologous gene region (O-antigen) and acid resistance gene system are “both being integrated into the Salmonella typhi Ty21a chromosome.”

This is a high bar for competitors using plasmids, episomes, or non-chromosomal integration, even if the expressed proteins are the same.

B. Heterologous Shigella sonnei O-antigen region

“heterologous Shigella sonnei O-antigen biosynthetic gene region”
Must include a wzz gene with one of two alternative definition modes:
1. the wzz locus DNA sequence “shares at least 95% sequence identity” with nucleic acids 4,511,904 to 4,513,010 of SEQ ID NO: 4; or
2. the DNA sequence “of nucleic acids 4,511,904 to 4,513,010 of SEQ ID NO: 4.”

This is a sequence-identity gate. It is not simply “a wzz homolog” or “a wzz gene from Shigella”; it is anchored to a specific SEQ ID mapping region.

C. Heterologous acid resistance biosynthetic system

“one or more heterologous Shigella acid resistance enzymes”
specifically framed to include “a YbaS gene” (in claim 1 as written, it says the acid system comprises one or more Shigella acid resistance enzymes comprising a YbaS gene)
dependent claims later lock to gad/gadA/gadB/gadC pairs.

D. Functional phenotype and immunogenicity requirements Claim 1 includes multiple functional/biological limitations:

(c) acid stability: the transgenic Ty21a is “more acid stable at pH 2.5” than Ty21a without the integrated acid resistance system
(d) immune response against virulent Shigella sonnei challenge
(e) immune response against virulent Salmonella typhi challenge
(a) and (b) expression: stable expression of heterologous Shigella sonnei O-antigen and stable expression of heterologous acid resistance enzymes.

From an enforceability perspective, these are typically proven with assay data and animal or in vitro models. For infringement analysis, the most likely dispute is whether an accused construct satisfies the phenotype, especially acid stability at pH 2.5 and immunogenicity endpoints.

Claim 1 “reads like” two coupled engineering requirements

The novelty position is implicit: the vaccine’s protective antigen (heterologous O-antigen) plus delivery-survival improvement (acid resistance) is claimed together in one chromosomally engineered strain. Competitors who swap in an O-antigen only strain without acid-stability engineering avoid the combination claim, while strains engineered only for acid stability avoid the O-antigen-linked claim.

How do the dependent claims narrow US 10,695,415 by sequence identity, specific genes, and additional O-antigen sources?

Short answer: Dependent claims substantially narrow claim 1 by tightening the specific locus definitions for wzz, requiring defined identity windows for the YbaS locus, adding a menu of alternative O-antigen regions from other bacteria, and specifying particular acid resistance genes (GadA/GadB/GadC) and vaccine use/outcomes.

Claim 2: broader wzz region identity mapping

Claim 2 narrows claim 1 by restricting the Shigella sonnei O-antigen gene region to one of two specified sequences:

(i) DNA sequence sharing at least 95% identity with nucleic acids 4,500,076 to 4,513,461 of SEQ ID NO: 4; or
(ii) DNA sequence of nucleic acids 4,500,076 to 4,513,461 of SEQ ID NO: 4.

This is effectively a larger defined region than the wzz segment in claim 1. Practically, it forces the O-antigen biosynthetic region boundaries to match (or near-match) the SEQ ID-defined interval.

Claim 3: YbaS sequence identity constraint

Claim 3 narrows the acid system by defining the YbaS DNA sequence:

(i) DNA sequence sharing at least 95% identity with nucleic acids 4,503,240 to 4,504,172 of SEQ ID NO: 1; or
(ii) the DNA sequence of nucleic acids 4,503,240 to 4,504,172 of SEQ ID NO: 1.

This reinforces that it is not enough to express a YbaS protein ortholog; the DNA sequence must fall within a high-identity window relative to the SEQ ID mapping.

Claims 10–12: acid resistance enzymes composition variants

These are the main gene-level dependents:

Claim 10: acid resistance enzymes comprise GadA and GadC
Claim 11: comprise GadB and GadC
Claim 12: comprise GadA, GadB, and GadC

Legally, these dependents set up multiple “design around” paths. However, because claim 1 already requires acid resistance enzymes comprising a YbaS gene, a competitor must still avoid the claim’s YbaS inclusion requirement, or fail the chromosomal integration requirement, or miss the specific O-antigen region constraints. Even if a competitor matches gad genes, they still need to satisfy the independent claim’s YbaS and O-antigen/wzz requirements to infringe claim 1.

Claim 4: alternative O-antigen gene region sources (menu claim)

Claim 4 adds an additional O-antigen region “from a bacterial strain selected from”:

Shigella dysenteriae
Shigella flexneri
Shigella boydii
Escherichia coli
Salmonella enterica serovars (spelled “Salmonela enterica serovars”)
Vibrio cholera serotypes
Enterobacter species
Yersinia species
Pseudomonas species

This dependent claim is not just “add more antigens.” It changes the claimed antigen breadth in the engineered chromosome. A competitor could attempt to avoid claim 1 by limiting the O-antigen region to S. sonnei only and not including this additional heterologous O-antigen region. Conversely, if an accused construct includes additional O-antigen regions from the listed taxa, claim 4 becomes relevant as a narrower “additional feature” layer.

Claim 5–9: composition and oral vaccine efficacy framing

Claim 5: composition of claim 4 plus a “carrier”
Claim 6: vaccine suitable for oral administration
Claim 7: administration reduces incidence of shigellosis after exposure to pathogenic Shigella sonnei
Claim 8: reduces incidence of typhoid fever after exposure to pathogenic S. typhi
Claim 9: reduces incidence of both shigellosis and typhoid fever after exposure to both pathogens

From a patent-interpretation standpoint, claims 7–9 function as product-by-use tied to population-level clinical outcomes. In litigation, these outcome statements are typically translated into evidentiary proof burdens rather than changing the genetic construct. In regulatory strategy, they also align to clinical endpoints for dual protection claims.

What patents likely cover adjacent Ty21a engineering themes, and how do sequence-identity and chromosomal integration affect the competitive landscape?

Short answer: Without the publication family context (application number, priority, and assignees) and without the listed patent family members, a comprehensive “US patent estate” cannot be enumerated accurately. This analysis therefore focuses on how US 10,695,415’s claim architecture shapes risk against potential competitors, independent of specific other patent numbers.

How claim structure affects infringement probability

Key elements that constrain infringement:

Chromosomal integration requirement

If competitors use plasmids or transient vectors, they generally avoid the claim’s integration limitation.
If competitors use site-specific chromosomal insertion, they still face claim risk.

Sequence-identity thresholds

The “at least 95% identity” clauses for wzz (and the extended O-antigen region in claim 2) and for YbaS (claim 3) make DNA-level similarity central.
Design-arounds may involve:
- using a different wzz ortholog with lower identity,
- replacing the exact SEQ-defined O-antigen interval boundaries,
- using a different YbaS allele not meeting the 95% identity window.

Coupled antigen and acid-resistance phenotype

Even if an alternative construct expresses Shigella O-antigen, missing acid stability at pH 2.5 relative to non-acid-engineered Ty21a may undercut infringement of claim 1’s phenotype limitation.
Even if acid resistance is improved, missing the constrained wzz or O-antigen gene region constraints may undercut infringement.

Immunogenicity to both pathogens

Claim 1 requires immune response against Shigella sonnei challenge and against S. typhi challenge.
Competitors may pursue constructs that provide improved S. typhi responses while swapping in a different antigen logic to avoid the dual-challenge language.

Practical risk map for alternative engineering designs

Competitor design choice	Likely claim 1 impact
Express S. sonnei O-antigen but with plasmid (not chromosomal)	Avoids chromosomal integration limitation
Chromosomal O-antigen but no YbaS acid system	Avoids acid resistance biosynthetic system requirement
Chromosomal acid system with different YbaS allele below 95% DNA identity to SEQ ID region	Likely avoids YbaS sequence identity limitation (claim 3)
wzz homolog with <95% DNA identity to SEQ ID region	Likely avoids claim 1/2 wzz gate
O-antigen region boundaries changed so it no longer matches SEQ-defined intervals	Likely avoids claim 2 O-antigen region constraint
Add extra O-antigen region from allowed taxa list in claim 4	Increases overlap with claim 4-dependent constructs
Oral vaccine but does not claim clinical reduction endpoints	Claims 6-9 are still product/vaccine by use; evidence of clinical outcome may be litigated

When does US 10,695,415 expire and how long does exclusivity typically last for a vaccine strain claim like this?

Short answer: A precise expiration schedule depends on the patent’s filing and priority dates, and whether it has terminal disclaimers or adjustments. Those facts are not provided in the prompt, so a correct exclusivity timeline cannot be produced.

What generic entry risks exist for a Ty21a-based oral vaccine protected by US 10,695,415?

Short answer: There is no “generic” entry in the conventional small-molecule sense for a live, engineered oral vaccine; “entry risk” translates into whether a developer can obtain licensure for a substantially engineered recombinant strain that avoids claim scope. The primary risk is that other developers use highly similar gene regions and chromosomal integration strategies, and their constructs still satisfy the 95% identity and gene-content requirements.

Patent “design-around” pathways that map to this claim set

The most straightforward off-ramps are claim-architecture aligned:

Remove chromosomal integration for one or both heterologous gene systems.
Use different wzz that fails the 95% DNA identity criterion or alter the O-antigen interval boundaries away from the SEQ-defined ranges.
Use different YbaS sequence that fails the 95% identity criterion.
Engineer acid stability using non-YbaS systems, or omit YbaS entirely.

How strong is the patent estate strength for US 10,695,415 based on claim precision?

Short answer: The claims are comparatively tight and technically specific (chromosomal integration, SEQ ID anchored DNA identity, and explicit gene set requirements). This precision often improves validity posture by reducing ambiguity and broadness, but it also creates clearer infringement escape routes for teams who change sequences or genomic boundaries.

Claim strength indicators

Tight genetic definitions: “at least 95% identity” and SEQ ID coordinate windows narrow claim scope and improve definiteness.
Combined functional phenotype: acid stability at pH 2.5 plus dual-pathogen immunogenicity adds another layer, but also introduces evidentiary complexity.
Menu limitation (claim 4): expands potential overlap when additional O-antigen regions are included, but remains bounded to listed taxa.

Claim weakness indicators

Dependence on defined SEQ ID coordinates: defendants can attack both infringement and validity by pointing to prior art with different allele boundaries or different identities.
Outcome language (claims 7–9): may create disputes over whether “reduces incidence” is established in the claimed population and whether the claimed construct necessarily causes the asserted outcomes.

What would be the key patent litigation issues for US 10,695,415?

Short answer: In a likely dispute, the technical issues dominate: whether the accused strain carries chromosomally integrated heterologous S. sonnei O-antigen and acid-resistance gene systems, whether the wzz and YbaS DNA sequences meet the 95% identity thresholds relative to the SEQ ID coordinates, and whether the accused construct exhibits improved acid stability at pH 2.5 and elicits immune responses to both pathogens.

Typical fact pattern for infringement analysis

Sequencing of accused constructs to compare against SEQ ID coordinate windows for:
- the wzz DNA sequence region required by claim 1
- the broader O-antigen gene region required by claim 2
- the YbaS DNA sequence region required by claim 3
Genomic mapping to confirm chromosomal integration versus plasmid insertion
Phenotype testing at pH 2.5 to compare acid stability relative to non-acid engineered Ty21a
Immunogenicity data using challenge models for S. sonnei and S. typhi

Key Takeaways

US 10,695,415 claims a dual-function live engineered Salmonella Typhi Ty21a strain: chromosomally integrated Shigella sonnei O-antigen biosynthetic region plus a Shigella acid resistance system with a YbaS gene.
The scope is narrowed by SEQ ID-anchored DNA identity requirements (95% identity) for wzz (and broader O-antigen intervals) and for YbaS.
Dependent claims add more constraints: specific gad gene combinations and an expanded menu of additional O-antigen sources.
Vaccine claims cover oral administration and population-level efficacy endpoints (reduced shigellosis/typhoid incidence after pathogen exposure), which would be litigated as product-by-use evidence.
“Design-around” is most feasible by altering chromosomal integration strategy and by changing the DNA sequences/boundaries for wzz, the O-antigen interval, and YbaS so they do not meet the 95% identity windows.

FAQs

1) Does US 10,695,415 cover plasmid-based expression of Shigella O-antigen in Ty21a?
The claim requires chromosomal integration of both heterologous gene regions into the Ty21a chromosome.

2) What is the most important sequence gate in the claims?
The 95% DNA sequence identity requirements anchored to SEQ ID coordinate ranges for wzz and for the YbaS gene.

3) Can a competitor avoid infringement by expressing acid resistance without YbaS?
Claim 1 requires an acid resistance biosynthetic system comprising Shigella acid resistance enzymes comprising a YbaS gene.

4) Do the vaccine efficacy claims (claims 7–9) change what the genetic construct must contain?
They add product-by-use outcome limitations; the construct is governed primarily by claims 1–6.

5) If a construct matches the antigen genes but fails acid stability at pH 2.5, does it infringe claim 1?
Claim 1 includes a requirement for improved acid stability at pH 2.5 compared with Ty21a lacking the integrated acid resistance system, so that phenotype becomes a central infringement issue.

References

No sources were provided in the prompt for patent bibliographic data, publication family members, prosecution history, Office Actions, or related litigation dockets. Without those citations, a numbered APA reference list cannot be generated from verified material.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bavarian Nordic A/s	VIVOTIF	typhoid vaccine live oral ty21a	Capsule	103123	December 15, 1989	⤷ Start Trial	2036-07-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,695,415

Summary for Patent: 10,695,415